Elekta stock dips as insiders buy and short interest remains high

Published on 09/17/2026 at 22:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Elekta stock closed at SEK 51.55 on Nasdaq Stockholm on September 16, 2026, modestly below recent levels as insider buying and short positions shape sentiment. A Barclays target of SEK 45.50 and nearly 15 percent of capital sold short underline the mixed risk-reward profile.

Moderner Bestrahlungsraum mit High-Tech-Linearbeschleuniger in blauem Klinik-Ambiente — Fotorealistischer Bestrahlungsraum zeigt Elekta AB SE0000163628 mit modernem Linearbeschleuniger in klinischer High-Tech-Umgebung, Illustration mit AI erstellt.

Elekta stock closed at SEK 51.55 on Nasdaq Stockholm on September 16, 2026, marking a modest decline for the Swedish medical technology group (ISIN SE0000163628) ahead of fresh insider activity and ongoing short interest in the name. The Elekta B share thus ended that trading day slightly below recent levels, setting the stage for renewed investor scrutiny around positioning and valuation.

Insider buying and short interest signal contrasting views

According to Placera on September 17, 2026, Elekta's chief financial officer Klara Eiritz purchased 3,655 Elekta B shares at a price of SEK 51.40 per share, for a total consideration of SEK 187,867 as reported via the Swedish Financial Supervisory Authority's insider register. This transaction slightly below the previous close suggests management confidence in the company at around the SEK 51 level.

As MarketScreener reported on September 17, 2026, hedge fund Millennium Capital Partners reduced its short position in Elekta below 0.5 percent of the share capital, meaning it no longer appears among the publicly disclosed short sellers in the stock. Despite this reduction, ten short sellers remain, and an aggregate 14.95 percent of Elekta's share capital is sold short, underlining that a significant portion of the market is still betting against the company.

Price data cited in the same MarketScreener overview show Elekta trading around SEK 51.38 to SEK 51.40 on September 17, 2026, corresponding to a daily decline of around 0.58 to 0.63 percent compared with the prior close of SEK 51.70 on Nasdaq Stockholm. At roughly SEK 51.40, the stock stands about 15.46 percent below a consensus target price of SEK 59.69 mentioned in the portal's data, illustrating that, despite heavy short interest, the average analyst target remains meaningfully above the current trading level.

Analyst stance and valuation context

Analyst sentiment on Elekta remains cautious. According to an item referenced by Affarsvarlden dated September 1, 2026, Barclays increased its price target for Elekta from SEK 44.50 to SEK 45.50 per share while reiterating an Underweight rating. This move lifted the target by SEK 1.00, but the new level still sits below the roughly SEK 51 trading price, implying downside of about 11 percent versus that intraday quote and reflecting continued concern about earnings quality and growth visibility.

In parallel, Swiss bank UBS continues to apply pressure to the stock. As noted by MarketScreener in its Elekta coverage updated around September 8, 2026, UBS reiterated a Sell recommendation on Elekta and highlighted persistent risks in the business, which contributes to the elevated short interest and cautious institutional positioning.

Short sellers and cautious brokers are balanced by more constructive fundamental signals. The same MarketScreener article notes that Elekta's profitability has recently improved and that the company's order backlog points to a recovery in demand for its radiotherapy and oncology solutions, although detailed figures and reporting periods are not fully broken out in the snippet. With an improving margin profile paired with a robust backlog, the debate around the stock increasingly turns on whether this operational progress is sufficient to justify a rerating from current levels around SEK 51.

Stock level and investor takeaway

Per price data cited in European equity overviews on September 17, 2026, Elekta B is trading on Nasdaq Stockholm under the ticker EKTA B at approximately SEK 51.40, modestly below the September 16, 2026 closing level of SEK 51.55 and prior close of SEK 51.70. At this level, the share price is notably under the average target of SEK 59.69 but above the more conservative Barclays target of SEK 45.50, capturing the tension between cautious analyst views and management's recent share purchases.